Drugs.com - New Drug Approvals

U.S. Food and Drug Administration Approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer

PRINCETON, N.J.--(BUSINESS WIRE)-- Apr 08, 2025 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy ® (ipilimumab) as a first-line treatment of adult...

Apr 14, 2025 - 04:43
 0
U.S. Food and Drug Administration Approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer
PRINCETON, N.J.--(BUSINESS WIRE)-- Apr 08, 2025 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy ® (ipilimumab) as a first-line treatment of adult...
Read More

Tags:

Previous Article

US-China trade war: Who'll blink first?

Next Article

Uplizna (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for...

Related Posts

Novartis Receives Third FDA Approval for Oral Fabhalta (iptacopan), the First and Only Treatment Approved in C3 Glomerulopathy

Novartis Receives Third FDA Approval for Oral Fabhalta ...

Mar 24, 2025  0

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) a...

Apr 14, 2025  0

Mirum’s Livmarli Now FDA Approved in Tablet Formulation

Mirum’s Livmarli Now FDA Approved in Tablet Formulation

Apr 15, 2025  0